The company Teva GmbH is circulating information on the fact that due to problems in the manufacture of Trisenox there will be a shortage on the European market during mid/late August 2017. However, these manufacturing issues do not affect the safety and efficacy of the product currently available on the market in any way. In order to continue to ensure reliable supply, Teva has decided to import the equivalent medicinal product Phenasen from Australia, for the EU.

information letter - full text (available in German only)